Abstract
It is hard to imagine the scale of impact that the molecular biology explosion and the sequencing of the human genome will have on medicine and drug discovery. A plethora of molecular targets combined with the prospect of fully individualised medicine are now the focal points for the pharmaceutical industry. Research investigators now have access to an armoury of tools, skills and knowledge that twenty, or even ten, years ago they could have only dreamed about.